Incyte has outlaid up to $2bn to acquire Star Therapeutics-owned subsidiary, Vega Therapeutics – adding a late-stage ...

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in ...

An expert observes a concerning rise in symptoms of bleeding disorders, with nearly 2–3 women reporting every week.

Incyte has agreed to acquire Vega Therapeutics for up to $2 billion, the companies said, in a deal designed to bolster the buyer’s hematology pipeline with antibody assets led by VGA039, a Phase III ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that the U.S. Food and Drug ...